Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Aquestive Therapeutics, Inc. - Common Stock
(NQ:
AQST
)
4.220
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 4, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Aquestive Therapeutics, Inc. - Common Stock
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Aquestive Therapeutics to Participate in 2023 Wedbush PacGrow Healthcare Conference
August 02, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Announces Positive Topline Pharmacokinetic Data for Anaphylm™ (epinephrine) Sublingual Film
July 27, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 7 and Host Conference Call on August 8 at 8:00 a.m. ET
July 25, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Earnings Outlook For Aquestive Therapeutics
↗
May 01, 2023
Via
Benzinga
Earnings Outlook For Aquestive Therapeutics
↗
March 06, 2023
Via
Benzinga
Aquestive Therapeutics to Present Positive Topline Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm ™ (epinephrine) Sublingual Film at Aspen Allergy Conference
July 25, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at Global Food Allergy Prevention Summit
July 06, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Provides Business Update and Announces Chief Medical Officer Appointment
June 29, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Reports Positive Results from Latest Clinical Studies Evaluating Pharmacokinetic and Pharmacodynamic Performance of Anaphylm ™ (epinephrine) Sublingual Film and Provides Findings from Recent Auto-Injector Clinical Study
May 31, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
↗
May 12, 2023
Via
Benzinga
Aquestive Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
May 02, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
April 26, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Receives Conditional FDA Acceptance of Proprietary Name Anaphylm™ for Lead Candidate AQST-109 (Epinephrine Sublingual Film)
April 20, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 2 and Host Conference Call on May 3 at 8:00 a.m. ET
April 18, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Expands License and Supply Agreement with Pharmanovia for Libervant™ (diazepam) Buccal Film to Additional Global Markets
March 29, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Business Update on Key 2023 Objectives
March 07, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference
March 01, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Report Fourth Quarter 2022 Financial Results and Recent Business Highlights on March 7 and Host Conference Call on March 8 at 8:00 a.m. ET
February 22, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for AQST-109 Epinephrine Sublingual Film at American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
February 21, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
February 15, 2023
Via
Benzinga
Aquestive Therapeutics Provides Business Update and Outlines Key 2023 Objectives
January 06, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Announces Completion of FDA End-of-Phase 2 Meeting For AQST-109 (epinephrine sublingual film)
December 22, 2022
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Announces Publication of Crossover Food Effect Study of Diazepam Nasal Spray in Epilepsia
November 29, 2022
Peer-reviewed data indicates that food significantly decreases and delays the absorption of diazepam dosed via nasal spray
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
November 15, 2022
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic Studies for AQST-109 (epinephrine sublingual film) at American Academy of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting
November 09, 2022
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Looking Into Aquestive Therapeutics's Return On Capital Employed
↗
November 09, 2022
According to data from Benzinga Pro, during Q3, Aquestive Therapeutics's (NASDAQ:AQST) reported sales totaled $11.46 million. Despite a 23.1% increase in earnings, the company posted a loss of $12.54...
Via
Benzinga
Aquestive Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
November 01, 2022
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Earnings Preview
↗
October 31, 2022
Aquestive Therapeutics (NASDAQ:AQST) is set to give its latest quarterly earnings report on Tuesday, 2022-11-01. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Aquestive Therapeutics Licenses Sympazan® (clobazam) Oral Film to Assertio Holdings, Inc.
October 27, 2022
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Announces Positive Decision in States’ Suboxone Antitrust Lawsuit on All Claims
October 24, 2022
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
